Tarsus Pharmaceuticals Inc
NASDAQ:TARS

Watchlist Manager
Tarsus Pharmaceuticals Inc Logo
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
Watchlist
Price: 42.97 USD -0.51% Market Closed
Market Cap: 1.8B USD

Intrinsic Value

The intrinsic value of one TARS stock under the Base Case scenario is 63.1 USD. Compared to the current market price of 42.97 USD, Tarsus Pharmaceuticals Inc is Undervalued by 32%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

TARS Intrinsic Value
63.1 USD
Undervaluation 32%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Tarsus Pharmaceuticals Inc

Valuation History Unavailable

Historical valuation for TARS cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
AI Assistant
AI Assistant
Ask me anything about Tarsus Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
Tarsus Pharmaceuticals Inc

Current Assets 480.8m
Cash & Short-Term Investments 407.9m
Receivables 64.2m
Other Current Assets 8.7m
Non-Current Assets 20m
Long-Term Investments 3m
PP&E 3.2m
Intangibles 8.1m
Other Non-Current Assets 5.7m
Efficiency

Free Cash Flow Analysis
Tarsus Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Tarsus Pharmaceuticals Inc

Revenue
233.7m USD
Cost of Revenue
-16.4m USD
Gross Profit
217.3m USD
Operating Expenses
-328.4m USD
Operating Income
-111.1m USD
Other Expenses
6.2m USD
Net Income
-104.9m USD
Fundamental Scores

TARS Profitability Score
Profitability Due Diligence

Tarsus Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Years Revenue Growth
Positive Gross Profit
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
35/100
Profitability
Score

Tarsus Pharmaceuticals Inc's profitability score is 35/100. The higher the profitability score, the more profitable the company is.

TARS Solvency Score
Solvency Due Diligence

Tarsus Pharmaceuticals Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Negative Net Debt
Low D/E
72/100
Solvency
Score

Tarsus Pharmaceuticals Inc's solvency score is 72/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

TARS Price Targets Summary
Tarsus Pharmaceuticals Inc

Wall Street analysts forecast TARS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for TARS is 72.27 USD with a low forecast of 51.51 USD and a high forecast of 89.25 USD.

Lowest
Price Target
51.51 USD
20% Upside
Average
Price Target
72.27 USD
68% Upside
Highest
Price Target
89.25 USD
108% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Tarsus Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for TARS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

TARS Insider Trading
Buy and sell transactions by insiders

What is the Intrinsic Value of one TARS stock?

The intrinsic value of one TARS stock under the Base Case scenario is 63.1 USD.

Is TARS stock undervalued or overvalued?

Compared to the current market price of 42.97 USD, Tarsus Pharmaceuticals Inc is Undervalued by 32%.

Back to Top